A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
ApexOnco Front Page
Recent articles
So who else could be interested in the oestrogen degrader?
Sunmo succeeds in a setting very similar to Starglo's.
The group is aiming for accelerated approval with the upcoming Alpacca trial.
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
When your investment case breaks down, why not just do the decent thing?
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.
